IFP Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.2K | Sell |
248
-223
| -47% | -$9.12K | ﹤0.01% | 3388 |
|
|
2026
Q1 | $18.9K | Sell |
471
-511
| -52% | -$11K | ﹤0.01% | 2808 |
|
|
2025
Q4 | $24.7K | Sell |
982
-127
| -11% | -$2.98K | ﹤0.01% | 2613 |
|
|
2025
Q3 | $25.1K | Buy |
1,109
+35
| +3% | +$816 | ﹤0.01% | 2468 |
|
|
2025
Q2 | $18.6K | Buy |
1,074
+948
| +752% | +$17.5K | ﹤0.01% | 2589 |
|
|
2025
Q1 | $2.75K | Sell |
126
-3,962
| -97% | -$109K | ﹤0.01% | 3040 |
|
|
2024
Q4 | $130K | Sell |
4,088
-93
| -2% | -$2.8K | ﹤0.01% | 1336 |
|
|
2024
Q3 | $121K | Sell |
4,181
-188
| -4% | -$6.96K | ﹤0.01% | 1324 |
|
|
2024
Q2 | $168K | Buy |
4,369
+671
| +18% | +$30.4K | 0.01% | 1124 |
|
|
2024
Q1 | $217K | Sell |
3,698
-31
| -0.8% | -$1.98K | 0.01% | 959 |
|
|
2023
Q4 | $223K | Sell |
3,729
-77
| -2% | -$3.91K | 0.01% | 901 |
|
|
2023
Q3 | $145K | Buy |
3,806
+1,862
| +96% | +$81.8K | 0.01% | 1110 |
|
|
2023
Q2 | $177K | Sell |
1,944
-41
| -2% | -$3.54K | 0.01% | 1078 |
|
|
2023
Q1 | $39K | Buy |
1,985
+1,981
| +49,525% | +$114K | ﹤0.01% | 1700 |
|
|
2022
Q4 | $1K | Buy |
+4
| New | +$212 | ﹤0.01% | 4279 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 3367 |
|
|
2021
Q2 | $0 | Buy |
+1
| New | +$52 | ﹤0.01% | 3054 |
|
IFP Advisors's APLS Position: Q2 2026 in Review
IFP Advisors reduced its Apellis Pharmaceuticals (APLS) stake by 47% in Q2 2026, selling an estimated $9.12K and leaving 248 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3388.
IFP Advisors first reported a position in APLS in Q2 2021 and has held it in 16 quarters since. The position peaked at $223K in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- IFP Advisors held 248 shares of Apellis Pharmaceuticals worth $10.2K as of Q2 2026.
- IFP Advisors sold 223 Apellis Pharmaceuticals shares in Q2 2026, an estimated $9.12K.
- Apellis Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3388 holding.
- IFP Advisors first reported a position in Apellis Pharmaceuticals in Q2 2021 and has held it in 16 quarters since.
- IFP Advisors's Apellis Pharmaceuticals position peaked at $223K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.